Does Digoxin Prevent Heart Failure in Rheumatic Patients?

Rheumatic heart disease continues to be a major health burden in India. Consequently, physicians often seek effective ways to manage symptoms and prevent complications. A recent landmark trial published in JAMA investigated the use of Digoxin in Rheumatic Heart Disease. Specifically, the study evaluated whether this therapy could reduce the combined risk of death and worsening heart failure. Furthermore, the findings provide much-needed evidence for a drug commonly used in clinical practice.

Benefits of Digoxin in Rheumatic Heart Disease

The multicenter Dig-RHD trial enrolled 1769 patients across twelve tertiary hospitals in India. Most of these participants had moderate to severe mitral stenosis or atrial fibrillation. Researchers randomized the patients to receive either oral digoxin or a matching placebo. Additionally, they monitored the participants for a median period of 2.1 years. Consequently, the team found that digoxin significantly reduced new-onset or worsening heart failure events. Therefore, this treatment offers a practical solution for symptomatic patients in resource-limited settings.

Clinical Outcomes and Safety Profile

The results showed an 18% reduction in the primary composite endpoint for those taking digoxin. Specifically, fewer patients in the digoxin group experienced worsening heart failure compared to the placebo group. However, the study did not find a significant difference in overall mortality rates between groups. Importantly, the risk of digoxin toxicity remained remarkably low at approximately 1%. Most suspected toxicity cases were minor and did not require hospitalization. Therefore, the researchers concluded that digoxin is generally safe and effective for this population. Overall, these findings should increase clinician confidence when prescribing this medication.

Frequently Asked Questions

Q1: What was the primary finding of the Dig-RHD trial?

The trial found that digoxin reduced the risk of death or worsening heart failure by 18% in patients with symptomatic rheumatic heart disease. This benefit was mainly driven by a reduction in heart failure episodes.

Q2: How safe was digoxin for the study participants?

The trial showed that digoxin is very safe for this patient population. Only about 1.1% of patients in the treatment group experienced suspected toxicity, and no toxicity-related deaths or hospitalizations occurred.

Q3: Should all rheumatic heart disease patients take digoxin?

The study focused on patients with symptomatic rheumatic heart disease, heart failure, or atrial fibrillation. Clinicians should evaluate individual patient needs and clinical status before starting treatment.

References

1. Karthikeyan G et al. Digoxin in Patients With Symptomatic Rheumatic Heart Disease: A Randomized Clinical Trial. JAMA. 2026 May 10. doi: 10.1001/jama.2026.7335. PMID: 42106990.
2. American College of Cardiology. Digoxin Improves Outcomes in Patients With Rheumatic Heart Disease. ACC News. March 30, 2026.
3. TCTMD. DIG-RHD: Digoxin Effective in Rheumatic Heart Disease. Michael O\’Riordan. April 06, 2026.